تداخلات لوماتيبيرون

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

…phenobarbital, phenytoin Antiarrhythmics Amiodarone (with ritonavir), quinidine (with ritonavir) Antimycobacterials Rifampin Antineoplastics Apalutamide, encorafenib, irinotecan, ivosidenib Antipsychotics Lurasidone (with ritonavir), pimozide Benzodiazepines Orally administered midazolam a , triazolam Ergot Derivatives Dihydroergotamine, ergonovine, ergotamine, methylergonovine… (نشرة أتازانافير، موانع الاستعمال)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (نشرة أزيلاستين وفلوتيكازون، التحذيرات والاحتياطات)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (نشرة إستازولام، التحذيرات)

The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (نشرة إسزوبيكلون، التحذيرات والاحتياطات)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

• Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (نشرة ألبرازولام، التحذيرات والاحتياطات)

…AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH ALCOHOL, BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Belladonna and opium suppositories expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (نشرة البلادونا والأفيون، تحذير مؤطر)

Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products: St. (نشرة إلفيتيغرافير وكوبيسيستات وإمتريسيتابين وتينوفوفير، موانع الاستعمال)

الجمع بين الكحول والأدوية المهدئة (الأفيونيات، البنزوديازيبينات، أدوية النوم، مرخيات العضلات) قد يسبب نعاسًا خطيرًا وتباطؤًا في التنفس وجرعة زائدة. (NIAAA, Harmful Interactions: Mixing Alcohol with Medicines)

…the description of tardive dyskinesia and its clinical detection, please refer to the sections on Information for Patients and ADVERSE REACTIONS . ) Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs and with amoxapine. (نشرة أموكسابين، التحذيرات)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (نشرة أوكسازيبام، التحذيرات)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

• Central Nervous System Depression Xyrem (sodium oxybate) is a CNS depressant. (نشرة أوكسيبات الصوديوم، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة أوكسيكودون، تحذير مؤطر)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Oxycodone hydrochloride tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (نشرة أوكسيكودون وباراسيتامول، تحذير مؤطر)

Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة أوكسيمورفون، تحذير مؤطر)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (نشرة أولوباتادين، التحذيرات والاحتياطات)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (نشرة أولوباتادين وموميتازون، التحذيرات والاحتياطات)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة أوليسيريدين، تحذير مؤطر)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة باراسيتامول وكودايين، تحذير مؤطر)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (نشرة بروموكريبتين، التحذيرات والاحتياطات)

…PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Promethazine HCl and Codeine Phosphate Oral Solution exposes patients and other users to the risks… (نشرة بروميثازين وكودايين، تحذير مؤطر)

• Respiratory Depression : May occur with LYRICA when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. (نشرة بريغابالين، التحذيرات والاحتياطات)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

…MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Pentazocine and Naloxone Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (نشرة بنتازوسين ونالوكسون، تحذير مؤطر)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوبرينورفين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وباراسيتامول وكافيين وكودايين، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتورفانول، تحذير مؤطر)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بيثيدين، تحذير مؤطر)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة تابنتادول، تحذير مؤطر)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة ترامادول، تحذير مؤطر)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة ترامادول وباراسيتامول، تحذير مؤطر)

• Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (نشرة تريازولام، التحذيرات والاحتياطات)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Avoid trimethobenzamide hydrochloride capsules in patients receiving other drugs that are likely to cause EPS (e.g. antipsychotics) [see Drug Interactions (7.2) ] . (نشرة تريميثوبنزاميد، التحذيرات والاحتياطات)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (نشرة تريهكسيفينيديل، التحذيرات)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with tetrabenazine tablets and other drugs that reduce dopaminergic transmission [see Drug Interactions (7.6) ]. (نشرة تيترابينازين، التحذيرات والاحتياطات)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (نشرة تيمازيبام، التحذيرات)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Alpha 1-adrenoreceptor antagonist: alfuzosin Anti-gout: colchicine, in patients with renal and/or hepatic impairment Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Cardiac Disorders: dronedarone, ivabradine, ranolazine Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine Herbal product: St. (نشرة دارونافير، موانع الاستعمال)

…antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Anti-gout: colchicine, in patients with renal and/or hepatic impairment Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Cardiac Disorders: dronedarone, ivabradine, ranolazine Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine Herbal product: St. (نشرة دارونافير وكوبيسيستات، موانع الاستعمال)

…Clinical Pharmacology (12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone… (نشرة درونيدارون، موانع الاستعمال)

Central nervous system (CNS) depressants: Concurrent use with alcohol or other CNS depressants is not recommended ( 5.1 ) (نشرة دوكسيلامين وبيريدوكسين، التحذيرات والاحتياطات)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (نشرة ديازيبام، التحذيرات)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (نشرة ديفينوكسيلات وأتروبين، موانع الاستعمال)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (نشرة ديوتيترابينازين، التحذيرات والاحتياطات)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة ريميفنتانيل، تحذير مؤطر)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (نشرة زاليبلون، التحذيرات)

The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (نشرة زولبيديم، التحذيرات والاحتياطات)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (نشرة سيبروفلوكساسين، التداخلات الدوائية)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (نشرة سيتريزين، التحذيرات والاحتياطات)

Based on its structural similarity to TCAs, concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the… (نشرة سيكلوبنزابرين، التداخلات الدوائية)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

• Respiratory Depression: May occur with NEURONTIN when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment. (نشرة غابابنتين، التحذيرات والاحتياطات)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (نشرة فالبينازين، التحذيرات والاحتياطات)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

• Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة فنتانيل، تحذير مؤطر)

…coadministered with the following drugs: Alpha 1-adrenoreceptor antagonist: Alfuzosin Antiarrhythmics: Flecainide (with ritonavir ), propafenone (with ritonavir ) Antimycobacterial: Rifampin Antipsychotic: Lurasidone (with ritonavir ), pimozide Ergot derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine GI motility agent: Cisapride Herbal product: St. (نشرة فوسامبرينافير، موانع الاستعمال)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (نشرة فينيلزين، موانع الاستعمال)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (نشرة كاربينوكسامين، التحذيرات والاحتياطات)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Colchicine (in patients with normal renal and hepatic function) Use With Caution Antipsychotics: Pimozide Contraindicated Pimozide: [See Contraindications ( 4.2 )] Quetiapine Lurasidone Quetiapine: Quetiapine is a substrate for CYP3A4, which is inhibited by clarithromycin. (نشرة كلاريثرومايسين، التداخلات الدوائية)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (نشرة كلورازيبات، التحذيرات)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (نشرة كلورديازيبوكسيد، التحذيرات)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (نشرة كلورديازيبوكسيد وكليدينيوم، التحذيرات)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (نشرة كلونازيبام، التحذيرات)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (نشرة كلونيدين، التحذيرات والاحتياطات)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة كودايين، تحذير مؤطر)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (نشرة كيتامين، التداخلات الدوائية)

This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (نشرة كيتوكونازول، موانع الاستعمال)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (نشرة لورازيبام، التحذيرات والاحتياطات)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة ليفورفانول، تحذير مؤطر)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (نشرة ليفوسيتريزين، التحذيرات والاحتياطات)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة مورفين، تحذير مؤطر)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (نشرة ميتاكسالون، التحذيرات والاحتياطات)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

• Tardive Dyskinesia (TD), Other Extrapyramidal Symptoms (EPS), and Neuroleptic Malignant Syndrome (NMS) : Avoid concomitant use of other drugs known to cause TD/EPS/NMS and avoid use in patients with Parkinson’s Disease. (نشرة ميتوكلوبراميد، التحذيرات والاحتياطات)

Managing Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, is a risk factor for respiratory depression and death [see Warnings and Precautions ( 5.2 )]. (نشرة ميثادون، تحذير مؤطر)

WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (نشرة ميدازولام، تحذير مؤطر)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة نالبوفين، تحذير مؤطر)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (نشرة نالميفين، التحذيرات والاحتياطات)

Neuropsychiatric agents suvorexant ↑ suvorexant Avoid concomitant use of suvorexant with PAXLOVID. aripiprazole, brexpiprazole, cariprazine, iloperidone, lumateperone, pimavanserin ↑ aripiprazole ↑ brexpiprazole ↑ cariprazine ↑ iloperidone ↑ lumateperone ↑ pimavanserin Dosage adjustment of aripiprazole, brexpiprazole, cariprazine, iloperidone, lumateperone, and… (نشرة نيرماتريلفير وريتونافير، التداخلات الدوائية)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (نشرة هيدروكسيزين، الاحتياطات)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة هيدروكودون، تحذير مؤطر)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction,… (نشرة هيدروكودون وإيبوبروفين، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة هيدروكودون وباراسيتامول، تحذير مؤطر)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION;… (نشرة هيدروكودون وكلورفينيرامين، تحذير مؤطر)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Hydrocodone bitartrate and homatropine methylbromide exposes patients and… (نشرة هيدروكودون وهوماتروبين، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death . (نشرة هيدرومورفون، تحذير مؤطر)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (نشرة ألوبيورينول، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (نشرة أمينوفيلين، التداخلات الدوائية)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (نشرة إنسولين أسبارت، التداخلات الدوائية)

Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (نشرة إنسولين ديتيمير، التداخلات الدوائية)

Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (نشرة إنسولين ديغلوديك، التداخلات الدوائية)

Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents… (نشرة إنسولين غلارجين، التداخلات الدوائية)

Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (نشرة إنسولين ليسبرو، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Patients should also be cautioned that the central nervous system depressant effects of intrathecal baclofen may be additive to those of alcohol and other CNS depressants. (نشرة باكلوفين، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Hyperpyrexia and Confusion Although not reported with pramipexole in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction,… (نشرة براميبيكسول، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

As with other sedative medications, there is wide interpatient variability in DIPRIVAN dosage requirements, and these requirements may change with time. (نشرة بروبوفول، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (نشرة برومفينيرامين وسودوإيفيدرين وديكستروميثورفان، التداخلات الدوائية)

The impairment may be amplified by concomitant use of other central-nervous-system depressants such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore such agents should either be eliminated or given in reduced dosage in the presence of promethazine… (نشرة بروميثازين، التحذيرات)

The impairment may be amplified by concomitant use of other central-nervous-system depressants such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore such agents should either be eliminated or given in reduced dosage in the presence of promethazine… (نشرة بروميثازين وديكستروميثورفان، التحذيرات)

Use with CNS depressants may result in an additive or potentiating effect. (نشرة بريمونيدين، التداخلات الدوائية)

Use with CNS depressants may result in an additive or potentiating effect. (نشرة بريمونيدين وتيمولول، التداخلات الدوائية)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with buprenorphine and naloxone sublingual tablets [see Warnings and Precautions (5.3) , Drug Interactions (7) ] . (نشرة بوبرينورفين ونالوكسون، التحذيرات والاحتياطات)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (نشرة بوبيفاكايين، التحذيرات والاحتياطات)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (نشرة بوبيفاكايين وأدرينالين، التحذيرات والاحتياطات)

Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (نشرة بوتالبيتال وأسبرين وكافيين، التداخلات الدوائية)

Butalbital and acetaminophen may enhance the effects of:other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (نشرة بوتالبيتال وباراسيتامول، التداخلات الدوائية)

Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (نشرة بوتالبيتال وباراسيتامول وكافيين، التداخلات الدوائية)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (نشرة بوسبيرون، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (نشرة بيكتيغرافير وإمتريسيتابين وتينوفوفير ألافيناميد، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

…medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid… (نشرة بيوغليتازون وغليميبيريد، التداخلات الدوائية)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

…accepted to prolong QT interval include Class 1A (e.g., quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin,… (نشرة توريميفين، التداخلات الدوائية)

Hyperpyrexia and Confusion: In clinical trials, four cases of a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, and altered consciousness), similar to that reported in association with the rapid dose reduction or withdrawal of other dopaminergic drugs, have been reported in association with… (نشرة تولكابون، الاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (نشرة ثيوفيلين، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (نشرة داريدوريكسانت، التحذيرات والاحتياطات)

Antipsychotics and Antianxiety Agents The concomitant administration of RYANODEX with antipsychotic and antianxiety agents may potentiate their effects on the central nervous system [see Warnings and Precautions ( 5.2 )] . (نشرة دانترولين، التداخلات الدوائية)

Since it may be difficult to distinguish neuroleptic malignant syndrome from malignant hyperpyrexia in the perioperative period, prompt treatment with dantrolene should be considered if increases in temperature, heart rate or carbon dioxide production occur. (نشرة دروبيريدول، التحذيرات)

Observe patients carefully when the dosage of NORTHERA is changed or when concomitant levodopa is reduced abruptly or discontinued, especially if the patient is receiving neuroleptics. (نشرة دروكسيدوبا، التحذيرات والاحتياطات)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (نشرة درونابينول، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

…increase certain actions or side effects of anticholinergic drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants,… (نشرة ديسيكلومين، التداخلات الدوائية)

Drug Interactions Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc). (نشرة ديفينهيدرامين، التداخلات الدوائية)

Use with CNS Depressants CORPHENA Oral Solution has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). Use in Activities Requiring Mental Alertness Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc. (نشرة ديكسكلورفينيرامين، التحذيرات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

The concomitant use of alcohol or other central nervous system depressants may have an additive effect. (نشرة ديمينهيدرينات، التحذيرات)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (نشرة راساجيلين، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (نشرة راميلتيون، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction of, withdrawal of, or changes in, dopaminergic therapy. (نشرة روبينيرول، التحذيرات والاحتياطات)

Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when ZONISADE is used with other drugs with sedative properties because of potential additive effects. (نشرة زونيساميد، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

CNS Depressants Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents. (نشرة سيبروهيبتادين، التحذيرات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (نشرة سيليجيلين، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

The following are examples of medication that may reduce the glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease… (نشرة غليبيزيد، التداخلات الدوائية)

…medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid… (نشرة غليميبيريد، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Possible risk factors for seizures include: concurrent major sedative-hypnotic drug withdrawal, recent therapy with repeated doses of parenteral benzodiazepines, myoclonic jerking or seizure activity prior to flumazenil administration in overdose cases, or concurrent cyclic antidepressant poisoning. (نشرة فلومازينيل، التحذيرات)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (نشرة فليبانسيرين، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval, such as class IA or class III antiarrhythmic medications, tricyclic antidepressants, macrolides, and antipsychotics [see Warnings and Precautions ( 5.2 )] . (نشرة فوسفومايسين، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Hyperpyrexia and Confusion Sporadic cases of a symptom complex resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reductions or withdrawal of certain antiparkinsonian agents such as levodopa, carbidopa-levodopa, or carbidopa-levodopa extended release. (نشرة كاربيدوبا، التحذيرات)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex that resembles neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in dopaminergic therapy. (نشرة كاربيدوبا وليفودوبا، التحذيرات والاحتياطات)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (نشرة كاربيدوبا وليفودوبا وإنتاكابون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

• Additive sedative effects when used with other CNS depressants including alcohol (5.1) (نشرة كاريزوبرودول، التحذيرات والاحتياطات)

Other CNS depressants, including alcohol, could potentiate the somnolence and sedation effect of EPIDIOLEX. (نشرة كانابيديول (بوصفة طبية)، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Chlorzoxazone use should also be discontinued if a patient develops abnormal liver enzymes (e.g., AST, ALT, alkaline phosphatase and bilirubin.) The concomitant use of alcohol or other central nervous system depressants may have an additive effect. (نشرة كلورزوكسازون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Use with CNS Depressants Clemastine has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). Use in Activities Requiring Mental Alertness Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc. (نشرة كليماستين، التحذيرات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

…others drugs or herbal products that are known to prolong the QT interval, including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, antipsychotics (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), or any other drug known to prolong the QT interval (e.g., pentamidine,… (نشرة لوبيراميد، التحذيرات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (نشرة ليدوكايين وأدرينالين، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex that resembles neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in dopaminergic therapy. (نشرة ليفودوبا، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (نشرة ليمبوريكسانت، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (نشرة موكسيفلوكساسين، التحذيرات والاحتياطات)

Additive Effects Since the effects of meprobamate and alcohol or meprobamate and other CNS depressants or psychotropic drugs may be additive,appropriate caution should be exercised with patients who take more than one of these agents simultaneously. (نشرة ميبروبامات، التحذيرات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (نشرة ميتيروسين، التداخلات الدوائية)

Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (نشرة ميثسكوبولامين، التداخلات الدوائية)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (نشرة ميثوكاربامول، التحذيرات والاحتياطات)

The CNS-depressant effect of BREVITAL may be additive with that of other CNS depressants, including ethyl alcohol and propylene glycol. (نشرة ميثوهيكسيتال، التحذيرات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (نشرة لوماتيبيرون، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

• Coadministration of meclizine hydrochloride with other CNS depressants, including alcohol, may result in increased CNS depression ( 7.1 ). (نشرة ميكليزين، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (نشرة نالوكسون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Some cases presented with features resembling neuroleptic malignant syndrome. (نشرة أتوموكسيتين، التداخلات الدوائية)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

In an uncontrolled open-label trial of CAPLYTA for up to 1 year in adult patients with stable schizophrenia, the percentages of patients with shifts in fasting glucose and insulin values from normal to high were 8% and 12%, respectively. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (نشرة إيبويتين ألفا، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (نشرة تياغابين، التحذيرات)

In an uncontrolled open-label trial of CAPLYTA for up to 1 year in adult patients with stable schizophrenia, the percentages of patients with shifts in fasting glucose and insulin values from normal to high were 8% and 12%, respectively. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (نشرة دوكسابرام، التحذيرات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (نشرة ديكستروأمفيتامين، التداخلات الدوائية)

Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (نشرة ريباغلينيد، التداخلات الدوائية)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

There have been no definitive drug-drug interaction studies to examine pharmacokinetic or pharmacodynamic interaction with other drugs; however, in humans, granisetron hydrochloride injection has been safely administered with drugs representing benzodiazepines, neuroleptics and anti-ulcer medications commonly prescribed with antiemetic treatments. (نشرة غرانيسيترون، التداخلات الدوائية)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Clinical Impact Although no clinically significant drug interactions with adjunctive SSRI/SNRIs in MDD were observed in CAPLYTA clinical trials, CAPLYTA’s moderate serotonin transporter (SERT) activity may increase the risk of SRI-associated adverse reactions (e.g., serotonin syndrome, hyponatremia). * See www.fda.gov/CYPandTransporterInteractingDrugs for examples… (نشرة لوماتيبيرون، التداخلات الدوائية)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (نشرة مونتيلوكاست، التداخلات الدوائية)

Clinical Impact Although no clinically significant drug interactions with adjunctive SSRI/SNRIs in MDD were observed in CAPLYTA clinical trials, CAPLYTA’s moderate serotonin transporter (SERT) activity may increase the risk of SRI-associated adverse reactions (e.g., serotonin syndrome, hyponatremia). * See www.fda.gov/CYPandTransporterInteractingDrugs for examples… (نشرة لوماتيبيرون، التداخلات الدوائية)